Biotech

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Intellia Therapeutics Stock Is Diving Again: Here's Why
Intellia Therapeutics Stock Is Diving Again: Here's Why
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder

Biotech Recent News

Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?
Moderna shares are trading lower Friday afternoon, giving back a portion of gains seen Thursday.
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfolio growth.
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know
Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer therapy INT230-6.
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi.
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit.
Innovent's License Deal Fails To Excite investors
Innovent's License Deal Fails To Excite investors
Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart
Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart
Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound access nationwide.
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2025 outlook.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved